BioStem Technologies Establishes $40 Million Committed Equity Facility With Roth Principal Investments
I'm LongbridgeAI, I can summarize articles.BioStem Technologies established a $40 million committed equity facility with Roth Principal Investments, effective September 18, 2026. The facility allows BioStem to sell common stock over 36 months for working capital and general corporate purposes. Key terms include VWAP-based pricing with discounts, a $1.00 threshold price, and ownership caps. BioStem will pay a $400,000 commitment fee. Additionally, a Registration Rights Agreement enables the resale registration of up to 12,050,000 shares.
BioStem Technologies entered a $40 million committed equity facility with Roth Principal Investments and a related Registration Rights Agreement. The facility allows the company, at its discretion, to sell common stock over up to 36 months from Commencement, with purchases priced off VWAP at fixed discounts and subject to a $1.00 threshold price, a 19.99% Nasdaq exchange cap unless priced above a threshold, and a 4.99% ownership cap. BioStem will pay a $400,000 cash commitment fee and expects to use proceeds for working capital and general corporate purposes. The registration rights provide for the resale registration of up to 12,050,000 shares and are required for the facility to commence.
Agreement 1: BioStem Technologies Establishes $40 Million Committed Equity Facility With Roth Principal Investments
- Agreement type: Committed equity facility via Common Stock Purchase Agreement
- Counterparty: Roth Principal Investments
- Signed / Effective: Sep 18 2026 / same
- Duration / Termination: Up to 36 months from Commencement
- Reason: Enhance liquidity and fund general corporate purposes
Agreement 2: BioStem Technologies Sets Registration Rights Deal to Register Up to 12.05M Shares
- Agreement type: Registration Rights Agreement for resale of up to 12,050,000 shares
- Counterparty: Roth Principal Investments
- Signed / Effective: Sep 18 2026 / same
- Duration / Termination: Survives facility termination
- Reason: Enable resale registration to support equity facility
Original SEC Filing: BioStem Technologies, Inc. [ BSEM ] - 8-K - Sep. 18, 2026